114 related articles for article (PubMed ID: 12362602)
1. [Molecular basis of arsenic action in promyelocytic leukemia cells].
Wysocki R; Wiśniewska E
Postepy Biochem; 2002; 48(2):121-30. PubMed ID: 12362602
[No Abstract] [Full Text] [Related]
2. [Arsenic and retinoic acid, toward targeted treatments of acute promyelocytic anemia?].
de Thé H
C R Seances Soc Biol Fil; 1998; 192(2):273-81. PubMed ID: 9759370
[TBL] [Abstract][Full Text] [Related]
3. How acute promyelocytic leukaemia revived arsenic.
Zhu J; Chen Z; Lallemand-Breitenbach V; de Thé H
Nat Rev Cancer; 2002 Sep; 2(9):705-13. PubMed ID: 12209159
[TBL] [Abstract][Full Text] [Related]
4. Triterpenoid CDDO-Im downregulates PML/RARalpha expression in acute promyelocytic leukemia cells.
Ikeda T; Kimura F; Nakata Y; Sato K; Ogura K; Motoyoshi K; Sporn M; Kufe D
Cell Death Differ; 2005 May; 12(5):523-31. PubMed ID: 15746941
[TBL] [Abstract][Full Text] [Related]
5. [Role of retinoic acid in the treatment of acute promyelocytic leukemia].
Gutiérrez de Guzmán J; Kantarjian H
Sangre (Barc); 1993 Oct; 38(5):375-8. PubMed ID: 8140499
[No Abstract] [Full Text] [Related]
6. cAMP signalling is decisive for recovery of nuclear bodies (PODs) during maturation of RA-resistant t(15;17) promyelocytic leukemia NB4 cells expressing PML-RAR alpha.
Duprez E; Lillehaug JR; Naoe T; Lanotte M
Oncogene; 1996 Jun; 12(11):2451-9. PubMed ID: 8649787
[TBL] [Abstract][Full Text] [Related]
7. Differentiation therapy of acute promyelocytic leukemia: clinical and molecular features.
Miller WH
Cancer Invest; 1996; 14(2):142-50. PubMed ID: 8597899
[No Abstract] [Full Text] [Related]
8. Genetics of APL and the molecular basis of retinoic acid treatment.
Casini T; Grignani F; Pelicci PG
Int J Cancer; 1997 Feb; 70(4):473-4. PubMed ID: 9033658
[No Abstract] [Full Text] [Related]
9. Molecular pathology of acute promyelocytic leukemia.
Chang KS
Hematol Pathol; 1993; 7(4):209-23. PubMed ID: 8113150
[No Abstract] [Full Text] [Related]
10. Acute promyelocytic leukemia: from genetics to treatment.
Grignani F; Fagioli M; Alcalay M; Longo L; Pandolfi PP; Donti E; Biondi A; Lo Coco F; Grignani F; Pelicci PG
Blood; 1994 Jan; 83(1):10-25. PubMed ID: 8274729
[No Abstract] [Full Text] [Related]
11. Growth suppression of acute promyelocytic leukemia cells having increased expression of the non-rearranged alleles: RAR alpha or PML.
Ahn MJ; Nason-Burchenal K; Moasser MM; Dmitrovsky E
Oncogene; 1995 Jun; 10(12):2307-14. PubMed ID: 7784078
[TBL] [Abstract][Full Text] [Related]
12. Marked for death.
Petrie K; Zelent A
Nat Cell Biol; 2008 May; 10(5):507-9. PubMed ID: 18454129
[No Abstract] [Full Text] [Related]
13. [All-trans retinoic acid therapy in acute promyelocytic leukemia--current status and prospect].
Kitamura K; Takeshita A; Ono R; Naoe T
Rinsho Ketsueki; 1996 Sep; 37(9):760-5. PubMed ID: 8914458
[No Abstract] [Full Text] [Related]
14. Retinoic acid and arsenic: towards oncogene-targeted treatments of acute promyelocytic leukaemia.
Quignon F; Chen Z; de Thé H
Biochim Biophys Acta; 1997 Dec; 1333(3):M53-61. PubMed ID: 9426202
[No Abstract] [Full Text] [Related]
15. Medicine. Poisonous contacts.
Kogan SC
Science; 2010 Apr; 328(5975):184-5. PubMed ID: 20378808
[No Abstract] [Full Text] [Related]
16. Inhibition of promyelocytic leukemia (PML)/retinoic acid receptor-alpha and PML expression in acute promyelocytic leukemia cells by anti-PML peptide nucleic acid.
Mologni L; Marchesi E; Nielsen PE; Gambacorti-Passerini C
Cancer Res; 2001 Jul; 61(14):5468-73. PubMed ID: 11454693
[TBL] [Abstract][Full Text] [Related]
17. Accelerated degradation of PML-retinoic acid receptor alpha (PML-RARA) oncoprotein by all-trans-retinoic acid in acute promyelocytic leukemia: possible role of the proteasome pathway.
Yoshida H; Kitamura K; Tanaka K; Omura S; Miyazaki T; Hachiya T; Ohno R; Naoe T
Cancer Res; 1996 Jul; 56(13):2945-8. PubMed ID: 8674046
[TBL] [Abstract][Full Text] [Related]
18. Tissue microarrays for hypothesis generation.
Dmitrovsky E
J Natl Cancer Inst; 2004 Feb; 96(4):248-9. PubMed ID: 14970265
[No Abstract] [Full Text] [Related]
19. Promyelocytic leukemia-specific PML-retinoic acid alpha receptor fusion protein interferes with erythroid differentiation of human erythroleukemia K562 cells.
Grignani F; Testa U; Fagioli M; Barberi T; Masciulli R; Mariani G; Peschle C; Pelicci PG
Cancer Res; 1995 Jan; 55(2):440-3. PubMed ID: 7529139
[TBL] [Abstract][Full Text] [Related]
20. Engaging a senescent response to cure leukemia.
Bourdeau V; Ferbeyre G
Nat Med; 2014 Feb; 20(2):123-4. PubMed ID: 24504403
[No Abstract] [Full Text] [Related]
[Next] [New Search]
